Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161025 · ClinicalTrials.gov registry record · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study of Solid Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 860
- Enrollment target
- 20
- Study locations
NCT06161025 is a Phase 2 study of Solid Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 860 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06161025, a Phase 2 study of Solid Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 860 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Topotecan
- DRUG R-DXd
- DRUG PLD
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center at Lennar - Coral Gables
- Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- Florida Cancer Specialists - Lake Mary
- Sylvester Cancer Center - Miami
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Sylvester Comprehensive Cancer Center at Plantation - Plantation
New York
- NHPP Imbert - Bay Shore
- Northwell Health, LLC PRIME - Lake Success
- Perlmutter Cancer Center at NYU Langone Hospital- Long Island - Mineola
- NYU Langone Health - New York
- NHPP LHH - New York
Indiana
- Community MD Anderson Cancer Center- East - Indianapolis
- Community MD Anderson Cancer Center- South - Indianapolis
- Community Health Network - MD Anderson - Indianapolis
New Jersey
- Valley Health System - Paramus
- Holy Name - Teaneck
Alaska
- Alaska Women's Cancer Care - Anchorage
Connecticut
- Yale University School of Medicine - New Haven
Kentucky
- St. Elizabeth Medical Center - Edgewood
Missouri
- Washington University School of Medicine Obstetrics and Gynecology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161025
The ClinicalTrials.gov registry entry for NCT06161025 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Cancer appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.
NCT06161025 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT06161025 about?
NCT06161025 is a clinical study titled "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
What is the current status of trial NCT06161025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 860 participants. The study started on 2024-02-27. Estimated completion is 2030-04-30.
What conditions does trial NCT06161025 study?
This clinical trial studies the following conditions: Solid Cancer.
What interventions are being tested in trial NCT06161025?
The interventions under investigation include: Paclitaxel (DRUG), Topotecan (DRUG), R-DXd (DRUG), PLD (DRUG).
Who is sponsoring clinical trial NCT06161025?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161025 being conducted?
This trial has 20 study locations across Alaska, Connecticut, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.